INSMED INC
About INSMED INC
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Its first commercial product is ARIKAYCE, a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders.
- 🔗 Insmed Announces Proposed $500 Million Public Offering of Common Stock
- 🔗 INSMED INCORPORATED
- 🔗 Insmed Announces Closing of Public Offering and Exercise of Option to Purchase Additional Shares
- 🔗 Insmed - 2026 Company Profile, Team, Funding, Competitors & Financials - Tracxn
- 🔗 Insmed Stock Price Today NASDAQ INSM - Investing.com Canada
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Insmed's first commercial product ARIKAYCE treats refractory nontuberculous mycobacterial lung infections.
- Company has a pipeline including brensocatib for inflammatory diseases.
- Publicly traded on NASDAQ: INSM with recent $500M proposed offering.
- Employs 1664 people as of recent data.
Ask StreetZero about INSMED INC
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account